A Cancer Target Revolution

How Revolution atypically inhibits SHP-2 and other difficult-to-drug targets for cancer

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation.

The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural and computational biology components to design and build complex compounds from chemical fragments. CEO Mark Goldsmith told BioCentury that the use of modular methods allows systematic and repetitive coupling of fragments to build variants of a compound

Read the full 722 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE